SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma gets US FDA nod to market generic Uroxatral tablets

20 Jul 2011 Evaluate

Sun Pharmaceutical Industries Ltd has received the US health regulator’s nod to market Alfuzosin Hydrochloride tablets, used in the treatment of prostatic hyperplasia, in the American market. Sun Pharma, being the first-to-file an abbreviated new drug application (ANDA) for generic Uroxatral ER with a para IV certification, received 180-day marketing exclusivity. Alfuzosin Hydrochloride extended release tablets, which are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia, have annual sales of nearly $250 million in the US.crackcrack

Sun Pharma Inds. Share Price

1872.40 25.10 (1.36%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×